Phaseline

Targets › TH

TH (Tyrosine 3-monooxygenase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Oct 2028.

Catalyzes the conversion of L-tyrosine to L-dihydroxyphenylalanine (L-Dopa), the rate-limiting step in the biosynthesis of catecholamines, dopamine, noradrenaline, and adrenaline. Uses tetrahydrobiopterin and molecular oxygen to convert tyrosine to L-Dopa. (UniProt, P07101)

Open in Phaseline: the race on TH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BlueRock Therapeuticsbemdaneprocel
Midbrain dopaminergic neuron progenitors derived from human embryonic stem cells
THPhase 3Parkinsons Disease (PD)Oct 2028

Conditions

Parkinsons Disease (PD) (1)

Modalities

other (1)

Companies

BlueRock Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.